Postzygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: A not-so-rare condition exposing to successive tumors
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Grégory Thomson und 24 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U830, Laboratory of Translational Research in Pediatric Oncology, PSL Research University, SIREDO Oncology Center, Institut Curie Research Cen…. Hauptthemen laut MEDLINE: SMARCB1 Protein, Rhabdoid Tumor, Mosaicism, Germ-Line Mutation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: "Marabout de ficelle" and "A.D.A.M" charities, French Society for the Fight against Childhood and Adolescent Cancer and Leukaemia, Federation of Childhood Cancer and Health.
Abstract (Originalsprache)
Background
Rhabdoid tumors (RT) are aggressive, rare tumors predominantly affecting young children, characterized by biallelic SMARCB1 gene inactivation. While most SMARCB1 alterations are acquired de novo, a third of cases exhibit germline alterations, defining Rhabdoid Tumors Predisposition Syndrome. With the increased sensitivity of next-generation sequencing (NGS), mosaicisms in genes linked to genetic diseases are more detectable. This study focuses on exploring SMARCB1 germline alterations, notably mosaicism in blood samples of children with RT and in parents, using a custom NGS panel.
Methods
A cohort of 280 children and 140 parents with germline analysis was studied. Germline DNA from 111 children with RT and 32 parents were reanalyzed with a custom NGS panel with 1500X average depth targeting the SMARCB1 gene to identify intragenic variants not detected with conventional low-sensitivity methods. Follow-up data was obtained for 77 patients.
Results
Nine previously undetected mosaicism cases were identified, totaling 17/280 patients with a mosaic variant (6.1%) in the cohort, with variant allele frequencies between 0.9% and 33%, thus highlighting the prior underestimation of its prevalence. Follow-up data showed that 4 out of 7 survivors with mosaic variants developed distinct novel tumors, 2 sharing SMARCB1 alterations with the initial tumor, emphasizing the potential clinical impact of SMARCB1 mosaicism.
Conclusions
The hitherto underestimated rate of SMARCB1 mosaicism in RT underscores the need for optimized genetic counseling and oncological monitoring. The findings have significant medical implications, considering the dire prognosis of RT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM U830, Laboratory of Translational Research in Pediatric Oncology, PSL Research University, SIREDO Oncology Center, Institut Curie Research Center, Paris, France.
- Somatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medecine, PSL Research University, Institut Curie Hospital, Paris, France.
- Department of Pediatric and Adolescent Oncology, Paris-Saclay University, Gustave Roussy Cancer Campus & INSERM U981, Molecular Predictors and New Targets in Oncology, Paris-Saclay University, Gustave Roussy, Villejuif,…
- Department of Neuropathology, GHU Paris-Psychiatry and Neurosciences, Sainte-Anne Hospital & UMR S1266, IMA-BRAIN, Paris Psychiatry and Neurosciences Institute (IPNP)/INSERM, Paris, France.
- Department of Genetics, PSL Research University, Institut Curie, Paris, France.
- Department of Neurosurgery, Paris-Cité University, Necker Sick Children's University Hospital, Paris, France.
ORCID-Profile: Grégory Thomson, Mathilde Filser, Léa Guerrini-Rousseau, Arnault Tauziede-Espariat, Kévin Beccaria, Natacha Entz-Werle, Laurence Brugieres, Ludovic Mansuy, Sophie Julia, Olivier Ingster, Olivier Delattre, Julien Masliah-Planchon, Franck Bourdeaut
Förderung
- "Marabout de ficelle" and "A.D.A.M" charities
- French Society for the Fight against Childhood and Adolescent Cancer and Leukaemia
- Federation of Childhood Cancer and Health
- ARC Foundation
- Institut Curie's SiRIC
- “Marabout de ficelle” and “A.D.A.M” charities
- Institut Curie’s SiRIC
Zitieren
APA
Thomson, G., Filser, M., Guerrini-Rousseau, L., Tauziede-Espariat, A., Bourneix, C., Gauthier-Villars, M., Simaga, F., Beccaria, K., Faure-Conter, C., Maureille, A., Zattara-Cannoni, H., Andre, N., Entz-Werle, N., Brugieres, L., Mansuy, L., Denizeau, P., Julia, S., Ingster, O., Lejeune, S., …, & Bourdeaut, F. (2024). Postzygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: A not-so-rare condition exposing to successive tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae122
Vancouver
Thomson G, Filser M, Guerrini-Rousseau L, Tauziede-Espariat A, Bourneix C, Gauthier-Villars M, et al. Postzygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: A not-so-rare condition exposing to successive tumors. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae122
BibTeX
@article{Thomson2024,
author = {Thomson, Grégory and Filser, Mathilde and Guerrini-Rousseau, Léa and Tauziede-Espariat, Arnault and Bourneix, Christine and Gauthier-Villars, Marion and Simaga, Fatoumata and Beccaria, Kévin and Faure-Conter, Cécile and Maureille, Aurélien and Zattara-Cannoni, Hélène and Andre, Nicolas and Entz-Werle, Natacha and Brugieres, Laurence and Mansuy, Ludovic and Denizeau, Philippe and Julia, Sophie and Ingster, Olivier and Lejeune, Sophie and Brahimi, Afane and Coupier, Isabelle and Bonadona, Valérie and Delattre, Olivier and Masliah-Planchon, Julien and Bourdeaut, Franck},
title = {Postzygotic mosaicism of SMARCB1 variants in patients with rhabdoid tumors: A not-so-rare condition exposing to successive tumors},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae122}
}
EUVIMED